Employees: 2,662
Size Xiangxue Pharmaceutical (300147.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $591M, the 3288th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥6.30 on 18 Nov 2026.
Performance Over six months the shares fell 40.9%, against -26.6% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 20 in its peer set.
Growth Revenue grew 2.9% over the last twelve months (peer median -2.5%); the operating margin is -38.5% (peer median 4.4%).
Valuation It trades at 3.7× enterprise value to sales against a peer median of 3.1× (8th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 50% a year for seven years (Req g). Recent delivered growth is -12%, so the hurdle is +63 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 38.7 points below its cost of capital (7.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.51B | CN¥1.59B | CN¥1.85B | CN¥2.29B | CN¥2.18B |
| Revenue growth | — | -14% | -19% | +5% | — |
| Gross profit | CN¥499M | CN¥327M | CN¥339M | CN¥685M | CN¥448M |
| EBITDA | n/a | CN¥75.2M | -CN¥873,910 | CN¥262M | CN¥51.1M |
| Net income | -CN¥1.45B | -CN¥1.39B | -CN¥859M | -CN¥389M | -CN¥530M |
| Free cash flow | CN¥25.8M | CN¥118M | -CN¥16.8M | CN¥208M | -CN¥139M |
| Capital expenditure | CN¥27.1M | CN¥21.5M | CN¥35.2M | CN¥56.0M | CN¥367M |
| Total debt | CN¥1.39B | CN¥4.02B | CN¥3.77B | CN¥3.79B | CN¥3.67B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300147.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +46.5% | -11.8% | highest of 20 |
| 6-month return | -40.9% | -26.6% | 5th lowest of 20 |
| Distance from 52-week high | -43.9% | -44.1% | 10th highest of 20 |
| Revenue growth (TTM) | +2.9% | -2.5% | 7th highest of 17 |
| Operating margin | -38.5% | 4.4% | 4th lowest of 16 |
| EV / Sales | 3.7× | 3.1× | 8th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 50.4% | -0.8% | most demanding of 11 |
| Growth delivered (Del g) | -12.3% | +2.5% | 3rd lowest of 11 |
| Hurdle (Req g minus delivered) | +62.7 pp | +0.0 pp | most demanding of 11 |
| ROIC minus cost of capital | -38.7 pp | -3.9 pp | lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Xiangxue Pharmaceutical 300147.SZ | China | $591M | -41% | +3% | -39% | 3.7× | 50.4% | -12.3% |
| Immix Biopharma IMMX | United States | $596M | -20% | n/a | n/a | n/a | n/a | n/a |
| Cullinan Therapeutics CGEM | United States | $585M | -37% | n/a | n/a | n/a | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $598M | -14% | -2% | 8% | 0.9× | -6.2% | +6.5% |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $583M | -20% | -6% | 5% | 2.6× | 20.9% | +21.9% |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $602M | -38% | +5% | -30% | 7.5× | n/a | n/a |
| Lepu Biopharma 2157.HK | Hong Kong | $580M | -43% | +47% | 7% | 4.5× | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $580M | -13% | +19% | -589% | 101.5× | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $604M | -31% | +2% | 4% | 1.2× | -0.6% | -1.6% |
| DBV Technologies DBV.PA | France | $604M | -46% | n/a | n/a | n/a | n/a | n/a |
| Abbisko Cayman 2256.HK | Hong Kong | $578M | -39% | -83% | -520% | 20.1× | n/a | n/a |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $577M | -26% | -21% | 32% | 1.9× | -15.4% | +2.8% |
| Chongkundang 185750.KS | South Korea | $609M | -27% | +6% | 4% | 0.5× | -6.6% | +5.4% |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $609M | -26% | -10% | -9% | 2.0× | -1.0% | -17.9% |
| Achieve Life Sciences QUIT | United States | $609M | n/a | n/a | n/a | n/a | n/a | n/a |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 25.1× | 9.1% | -25.1% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $612M | -52% | -13% | 10% | 3.3× | 10.1% | +2.1% |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $612M | -14% | -3% | -1% | 2.4× | 10.9% | -5.9% |
| Orchid Pharma ORCHPHARMA.NS | India | $613M | +30% | +11% | 0% | 6.1× | n/a | n/a |
| Alumis ALMS | United States | $569M | -80% | -67% | -5,375% | 23.9× | n/a | n/a |
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 3.0× | -8.7% | +8.8% |